AIM: To test the hypothesis that enhancement of the activity of heme oxygenase can interfere with processes of fibrogenesis associated with recurrent liver injury, we investigated the therapeutic potential of over-expression of heme oxygense-1 in a CCl(4)-induced micronodular cirrhosis model. METHODS: Recombinant adeno-associated viruses carrying rat HO-1 or GFP gene were generated. 1x 10(12) vg of adeno-associated viruses were administered through portal injection at the time of the induction of liver fibrosis. RESULTS: Conditioning the rat liver with over-expression of HO-1 by rAAV/HO-1 significantly increased the HO enzymatic activities in a stable manner. The development of micronodular cirrhosis was significantly inhibited in rAAV/HO-1-transduced animals as compared to controls. Portal hypertension was markedly diminished in rAAV/HO-1-transduced animals as compared to controls, whereas there are no significant changes in systolic blood pressure. This finding was accompanied with improved liver biochemistry, less infiltrating macrophages and less activated hepatic stellate cells (HSCs) in rAAV/HO-1-transduced livers. CONCLUSION: Enhancement of HO activity in the livers suppresses the development of cirrhosis.
AIM: To test the hypothesis that enhancement of the activity of heme oxygenase can interfere with processes of fibrogenesis associated with recurrent liver injury, we investigated the therapeutic potential of over-expression of heme oxygense-1 in a CCl(4)-induced micronodular cirrhosis model. METHODS: Recombinant adeno-associated viruses carrying ratHO-1 or GFP gene were generated. 1x 10(12) vg of adeno-associated viruses were administered through portal injection at the time of the induction of liver fibrosis. RESULTS: Conditioning the rat liver with over-expression of HO-1 by rAAV/HO-1 significantly increased the HO enzymatic activities in a stable manner. The development of micronodular cirrhosis was significantly inhibited in rAAV/HO-1-transduced animals as compared to controls. Portal hypertension was markedly diminished in rAAV/HO-1-transduced animals as compared to controls, whereas there are no significant changes in systolic blood pressure. This finding was accompanied with improved liver biochemistry, less infiltrating macrophages and less activated hepatic stellate cells (HSCs) in rAAV/HO-1-transduced livers. CONCLUSION: Enhancement of HO activity in the livers suppresses the development of cirrhosis.
Authors: L E Otterbein; F H Bach; J Alam; M Soares; H Tao Lu; M Wysk; R J Davis; R A Flavell; A M Choi Journal: Nat Med Date: 2000-04 Impact factor: 53.440
Authors: C D Ferris; S R Jaffrey; A Sawa; M Takahashi; S D Brady; R K Barrow; S A Tysoe; H Wolosker; D E Barañano; S Doré; K D Poss; S H Snyder Journal: Nat Cell Biol Date: 1999-07 Impact factor: 28.824
Authors: T Kyokane; S Norimizu; H Taniai; T Yamaguchi; S Takeoka; E Tsuchida; M Naito; Y Nimura; Y Ishimura; M Suematsu Journal: Gastroenterology Date: 2001-04 Impact factor: 22.682
Authors: N Goda; K Suzuki; M Naito; S Takeoka; E Tsuchida; Y Ishimura; T Tamatani; M Suematsu Journal: J Clin Invest Date: 1998-02-01 Impact factor: 14.808
Authors: N Makino; M Suematsu; Y Sugiura; H Morikawa; S Shiomi; N Goda; T Sano; Y Nimura; K Sugimachi; Y Ishimura Journal: Hepatology Date: 2001-01 Impact factor: 17.425
Authors: Adriana M Salazar-Montes; Luis D Hernández-Ortega; Martha S Lucano-Landeros; Juan Armendariz-Borunda Journal: World J Gastroenterol Date: 2015-04-07 Impact factor: 5.742
Authors: Jakob Wollborn; Christian Wunder; Jana Stix; Winfried Neuhaus; Rapahel R Bruno; Wolfgang Baar; Sven Flemming; Norbert Roewer; Nicolas Schlegel; Martin A Schick Journal: J Pharmacol Pharmacother Date: 2015 Jan-Mar
Authors: Giacomo Canesin; Linda Feldbrügge; Guangyan Wei; Lubica Janovicova; Monika Janikova; Eva Csizmadia; Juliana Ariffin; Andreas Hedblom; Zachary T Herbert; Simon C Robson; Peter Celec; Kenneth D Swanson; Imad Nasser; Yury V Popov; Barbara Wegiel Journal: iScience Date: 2022-08-20